Xenon Pharmaceuticals (XENE) is undervalued given azetukalner's late-stage potential to transform epilepsy and mood disorder ...

GLP-1 RA therapy linked to significantly lower risk for epilepsy compared with DPP4-i use among adults with T2DM.

Individuals with focal onset epilepsy treated with azetukalner experienced sustained monthly seizure reduction and evidence of seizure freedom up to 48 months, according to data presented at the ...

NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that it has filed a Premarket Approval Supplement (PMA-S) ...

Kyverna Therapeutics announced positive topline data from a phase II trial of mivocabtagene autoleucel, a chimeric antigen ...

Epilepsy is when the brain has an electrical misfire that causes multiple seizures. And depending on where the misfire takes place, the seizure will have different effects, such as freezing you or ...

Psychological interventions may be effective for achieving freedom from functional seizures, according to new practice ...

A new analysis suggests that people with type 2 diabetes who use GLP-1 medications like Ozempic, Trulicity or Victoza may be ...

Over 10 million people with epilepsy qualify as surgical candidates worldwide, with 1.4 million new potential surgical ...

AI-powered registries may improve epilepsy care by extracting data from incomplete medical records, easing the burden on clinicians when decisions are necessary regarding surgical evaluations, data ...

Learn How to Double Your Impact!When a loved one lives with epilepsy, the journey is more than medical. It’s emotional, social, and deeply personal. An employer matching gift can have double the ...

Children referred to a first seizure clinic often see a neurologist epilepsy specialist within 1 week for timely diagnosis ...